ResearchRSS2 days ago
Scientists discovered that blocking a protein pathway called JNK in the body may help treat spinal muscular atrophy (SMA), a disease that weakens muscles. In mice with severe SMA, blocking this pathway reduced how bad the disease got and helped the mice live longer. This new approach could work by itself or combined with medicines that are already approved for SMA.
WHY IT MATTERSIf this JNK pathway blocking approach moves to human trials, it could offer SMA patients a new treatment option, potentially as a combination therapy with existing approved drugs like nusinersen or onasemnogene abeparvovec.
ResearchRSS2 days ago
Researchers found that data from smartphones and wearable devices, collected over several years through a health app, can help doctors identify people with a rare lung disease called idiopathic pulmonary arterial hypertension (IPAH) earlier than before. The study used information like heart rate and activity levels from the My Heart Counts app to spot differences between people with IPAH and healthy people. This discovery could lead to faster diagnosis of this serious condition.
WHY IT MATTERSEarlier detection of IPAH could allow patients to start treatment sooner, potentially slowing disease progression and improving outcomes for this condition that currently has no cure.
ResearchRSS2 days ago
Scientists studied how spinal muscular atrophy (SMA) damages the connections between nerves and muscles. They found that in people with SMA, these nerve-muscle connections don't develop properly right after birth, making them weak and unable to work well before nerve cells start dying. This early problem may be an important part of how SMA causes muscle weakness.
WHY IT MATTERSUnderstanding that nerve-muscle connection problems happen early in SMA—before nerve cell loss—could lead to new treatments that target this early stage rather than only treating later damage.
ResearchRSS2 days ago
Researchers found that a simple electrical test using surface electrodes on the skin can measure nerve signals in people with spinal muscular atrophy (SMA). These signals were much weaker in SMA patients compared to healthy people, which suggests this test could be a useful way to track how the disease changes over time.
WHY IT MATTERSIf validated, this non-invasive surface electrode test could provide a faster, easier, and cheaper way to monitor SMA progression in clinical trials and patient care compared to current muscle strength assessments.
ResearchRSS2 days ago
Scientists found that haloperidol, a medication normally used to treat psychiatric conditions, may help treat spinal muscular atrophy (SMA) by increasing levels of a protein called SMN that is missing or low in SMA patients. In laboratory tests with mouse cells and human patient cells, haloperidol helped nerve cells survive longer, reduced harmful inflammation, and improved movement. This suggests haloperidol could potentially be used alongside or instead of current SMA treatments.
WHY IT MATTERSIf haloperidol proves effective in human trials, SMA patients could potentially benefit from a medication that already exists and is FDA-approved, potentially offering a faster path to treatment than developing entirely new drugs.
ResearchRSS2 days ago
A study of 34 patients in Hong Kong found that Evrysdi (a medicine taken by mouth) helped children and adults with spinal muscular atrophy (SMA) move better and feel better in their daily lives. Patients who had never taken SMA medicine before saw the biggest improvements. The good results lasted for up to three years.
WHY IT MATTERSThis real-world evidence from Asian patients shows Evrysdi works well outside of clinical trials, which may help doctors decide if it's the right treatment for SMA patients in your region.
ResearchBIORXIV5 days ago
Researchers studied blood samples from children with dengue virus infection to find early warning signs that could predict who will develop severe disease. By analyzing proteins in the blood, they identified markers related to inflammation and blood vessel damage that appear in children who get sicker. This discovery could help doctors quickly identify which children need more intensive care.
WHY IT MATTERSIf validated, these protein markers could enable doctors to predict dengue severity within hours of diagnosis in children, allowing earlier intervention before complications like hemorrhagic fever or shock develop.